STOCK TITAN

Exelixis to Webcast Fireside Chat as Part of the William Blair Biotech Focus Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Exelixis (NASDAQ: EXEL) will participate in a pre-recorded fireside chat at the William Blair Biotech Focus Conference 2022, available on-demand starting July 11, 2022. Investors can access the webcast on www.exelixis.com under the News & Events section. Replays will be available for 30 days. Founded in 1994, Exelixis focuses on developing treatments for challenging cancers and has several products on the market, including CABOMETYX® and COMETRIQ®. They are committed to advancing cancer therapies through innovative drug discovery.

Positive
  • None.
Negative
  • None.

-- Presentations to be webcast on www.exelixis.com --

ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a pre-recorded fireside chat at the William Blair Biotech Focus Conference 2022, which will be available to view on-demand beginning Monday, July 11, 2022.

To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the presentations to ensure adequate time for any software download that may be required to listen to the webcasts. Replays will also be available at the same location for at least 30 days.

About Exelixis

Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model system genetics, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. Our discovery efforts have resulted in four commercially available products, CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib), COTELLIC® (cobimetinib) and MINNEBRO® (esaxerenone), and we have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting in our business to maximize the potential of our pipeline. We are supplementing our existing therapeutic assets with targeted business development activities and internal drug discovery – all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis is a member of the Standard & Poor’s (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies. For more information about Exelixis, please visit www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.

Exelixis, the Exelixis logo, CABOMETYX and COMETRIQ are registered U.S. trademarks of Exelixis.
COTELLIC is a registered trademark of Genentech, Inc.
MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Investors Contact:

Varant Shirvanian

Associate Director, Investor Relations

Exelixis, Inc.

650-837-7917

vshirvanian@exelixis.com

Media Contact:

Hal Mackins

For Exelixis, Inc.

415-994-0040

hal@torchcommunications.com

Source: Exelixis, Inc.

FAQ

What is the date of Exelixis' presentation at the William Blair Biotech Focus Conference?

Exelixis will present at the William Blair Biotech Focus Conference on July 11, 2022.

How can I access the Exelixis fireside chat?

You can access the Exelixis fireside chat at www.exelixis.com under the News & Events section.

How long will the Exelixis presentation be available for replay?

The Exelixis presentation will be available for replay for 30 days.

What are the main products offered by Exelixis?

Exelixis markets products such as CABOMETYX® and COMETRIQ® for oncology treatment.

What is the focus of Exelixis as a biotechnology company?

Exelixis focuses on developing and commercializing new medicines for difficult-to-treat cancers.

Exelixis Inc

NASDAQ:EXEL

EXEL Rankings

EXEL Latest News

EXEL Stock Data

9.52B
281.04M
1.59%
89.36%
2.77%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
ALAMEDA